Lantheus initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Paul Choi initiated coverage of Lantheus (LNTH) with a Buy rating and $143 price target The firm says concerns about Pylarify growth overdone as the company has “best-in-class” infrastructure for exposure to the “attractive” theranostics and Alzheimer’s thematics. Goldman estimates Lantheus shares offer at an attractive entry point at these levels as Street estimates are underestimating Pylarify growth, the analyst tells investors in a research note. The firm believes Alzheimer’s disease diagnostics could emerge as meaningful drivers with an opportunity to unlock an over $1.5B market opportunity.